Roivant Sciences (ROIV) Status update summary

Settlement Overview

• A $2.25 billion global settlement was reached with Moderna, resolving all COVID-19 vaccine patent litigation, including a $950 million upfront payment due July 2026 and a $1.3 billion contingent on the outcome of a Section 1498 legal appeal, with robust credit protections in place.

• Moderna receives a global non-exclusive license for SM-102/LNP-containing mRNA vaccines for infectious diseases, with no further royalties due beyond the lump sum payments.

• Moderna consents to a judgment of infringement and no invalidity on four Genevant/Arbutus patents, validating the inventors' work.

• If the appeal is resolved in favor, the $1.3 billion payment is made; if overturned by the Supreme Court, funds are returned.

• The settlement is among the largest patent case outcomes in history, potentially the largest in biopharma and second largest in any industry.

Financial and Capital Allocation Implications

• Roivant expects to receive 60%-70% of the proceeds, with an effective tax rate of 10%-15% on its share; the remainder goes to Arbutus and others.

• Proceeds will be used to invest in the pipeline, upcoming launches, new opportunities, and accelerated capital return to shareholders.

• Share buyback program expanded to $1 billion, including a new $500 million authorization, with an aggressive approach to returning capital.

• Capital allocation for future settlements, such as with Pfizer, will balance share buybacks, pipeline investment, and business development.

• The settlement provides significant near-term cash inflow and reduces uncertainty, allowing focus on core business and ongoing litigation.

Legal and Strategic Context

• Moderna retains the right to appeal solely on whether liability for infringement falls on Moderna or U.S. taxpayers under government contracts.

• The Section 1498 appeal is expected to resolve in 18-36 months, with prior rulings in favor of the company.

• Moderna's settlement covers about one-third of the global COVID vaccine market; Pfizer-BioNTech litigation remains ongoing and is expected to be pursued aggressively.

• Judgment of no invalidity on patents strengthens position in the Pfizer case, though Pfizer can still challenge validity.

• No specific damages sought from Pfizer disclosed; outcome of Moderna case seen as supportive but not determinative for Pfizer negotiations.